SRDX Surmodics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SRDX

Price (delayed)

$32.49

Market cap

$463.31M

P/E Ratio

33.84

Dividend/share

N/A

EPS

$0.96

Enterprise value

$459.76M

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics ...

Highlights
The company's EPS has surged by 146% QoQ and by 137% YoY
The net income has surged by 145% since the previous quarter and by 138% year-on-year
SRDX's quick ratio has surged by 69% year-on-year but it is down by 5% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.surmodics.com
Peers: NKTR TMO ALKS ENZ

Key stats

What are the main financial stats of SRDX
Market
Shares outstanding
14.26M
Market cap
$463.31M
Enterprise value
$459.76M
Valuations
Price to earnings (P/E)
33.84
Price to book (P/B)
3.73
Price to sales (P/S)
3.22
EV/EBIT
22.04
EV/EBITDA
15.16
EV/Sales
3.22
Earnings
Revenue
$142.96M
EBIT
$20.86M
EBITDA
$30.32M
Free cash flow
$22.56M
Per share
EPS
$0.96
Free cash flow per share
$1.59
Book value per share
$8.71
Revenue per share
$10.1
TBVPS
$8.09
Balance sheet
Total assets
$182.81M
Total liabilities
$58.86M
Debt
$29.48M
Equity
$123.95M
Working capital
$65.07M
Liquidity
Debt to equity
0.24
Current ratio
4.39
Quick ratio
2.77
Net debt/EBITDA
-0.12
Margins
EBITDA margin
21.2%
Gross margin
79.1%
Net margin
9.4%
Operating margin
13.5%
Efficiency
Return on assets
7.3%
Return on equity
11.3%
Return on invested capital
24.4%
Return on capital employed
12.7%
Return on sales
14.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRDX stock price

How has the Surmodics stock price performed over time
Intraday
-5.96%
1 week
24.15%
1 month
20.51%
1 year
41.14%
YTD
-10.62%
QTD
10.74%

Financial performance

How have Surmodics's revenue and profit performed over time
Revenue
$142.96M
Gross profit
$113.1M
Operating income
$19.3M
Net income
$13.5M
Gross margin
79.1%
Net margin
9.4%
The operating income has soared by 170% YoY and by 60% from the previous quarter
SRDX's operating margin has surged by 150% year-on-year and by 55% since the previous quarter
The net income has surged by 145% since the previous quarter and by 138% year-on-year
The net margin has soared by 135% since the previous quarter and by 127% year-on-year

Growth

What is Surmodics's growth rate over time

Valuation

What is Surmodics stock price valuation
P/E
33.84
P/B
3.73
P/S
3.22
EV/EBIT
22.04
EV/EBITDA
15.16
EV/Sales
3.22
The company's EPS has surged by 146% QoQ and by 137% YoY
Surmodics's equity has increased by 21% YoY
The stock's price to book (P/B) is 15% less than its 5-year quarterly average of 4.4
SRDX's P/S is 39% below its 5-year quarterly average of 5.3 and 2.4% below its last 4 quarters average of 3.3
SRDX's revenue is up by 39% YoY and by 3.4% QoQ

Efficiency

How efficient is Surmodics business performance
The ROIC has soared by 162% YoY and by 53% from the previous quarter
The company's return on sales has surged by 155% YoY and by 52% QoQ
SRDX's return on assets has surged by 135% since the previous quarter and by 134% year-on-year
The ROE has soared by 135% from the previous quarter and by 135% YoY

Dividends

What is SRDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRDX.

Financial health

How did Surmodics financials performed over time
SRDX's quick ratio has surged by 69% year-on-year but it is down by 5% since the previous quarter
The current ratio has grown by 37% YoY but it has contracted by 9% from the previous quarter
The debt is 76% smaller than the equity
Surmodics's equity has increased by 21% YoY
The debt to equity has contracted by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.